Who Paid My Doc
A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr
Research payments
$12,670,712
Through program year 2023, $12,670,712 in research payments was reported against A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr, across 3,197 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $1,526,374 | 326 |
| 2022 | Research | $11,127,917 | 2,865 |
| 2021 | Research | $16,420 | 6 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Stephen Stamatis Weatherford, TX Named on 135 payments
- Richard Ondrizek Burleson, TX Named on 131 payments
- Andrew Wagner Saginaw, MI Named on 126 payments
- Cynthia Robbins Fort Worth, TX Named on 114 payments
- Dawnette Peppler Arlington, TX Named on 111 payments
- Merlin Fausett Missoula, MT Named on 109 payments
- Vanna Gold Lampasas, TX Named on 106 payments
- John Roberts Plano, TX Named on 104 payments
- Guy Middleton Dothan, AL Named on 104 payments
- Gary Gregerson Nampa, ID Named on 104 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.